AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03300115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
Study NCT03172182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a 360-degree VR video tour
Description: At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
Study NCT02990312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus + Maraviroc
Description: Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
Study NCT00585416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047
Description: CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
Study NCT01105754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted Prompting Intervention MPI
Description: Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.~Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form.
Study NCT03128008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Single arm non randomized open label study. Subjects will receive standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
Study NCT03128008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
Study NCT03128008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily hyperfractionated radiation therapy
Description: All subjects will receive 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
Study NCT02504515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: World Health Organization Quality of Life Bref Questionnaire
Description: The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.~The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials.
Study NCT03149718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention Medication Therapy Management
Description: BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
Study NCT03149718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Counseling (SMC)
Description: Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
Study NCT03476213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group TCI
Description: Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
Study NCT03476213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group TIVA
Description: Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
Study NCT01178554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychotherapy
Description: Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
Study NCT01178554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: evidence-based treatment
Description: Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
Study NCT01178554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modular evidence-based treatment
Description: Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita \& Weisz, 2004)
Study NCT01443715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care IPT-A (SCIPT-A)
Description: Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
Study NCT01443715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard treatment in the community
Study NCT00414713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: red blood cell transfusion
Description: red blood cell transfusion
Study NCT02582567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
Study NCT02457208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (H)
Study NCT02457208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin (R)
Study NCT02457208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)
Study NCT02457208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol (E)
Study NCT00705354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacitracin
Description: Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
Study NCT00705354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopore sponge soaked with saline
Description: Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
Study NCT00928447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: 0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
Study NCT00928447 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25 mL ID syringe push bolus injection of placebo control
Study NCT01436188 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard CSR sampling procedure
Description: standard frequent CSF sampling procedure for 36 hours
Study NCT01436188 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Alternate frequency CSR sampling procedure
Description: an alternative frequency of CSF sampling procedure for 36 hours
Study NCT01436188 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard frequent CSR sampling procedure with 800 mg ibuprofen
Description: standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
Study NCT01436188 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard CSR sampling procedure
Description: standard frequent CSF sampling procedure for 36 hours.
Study NCT01436188 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Alternative lower frequency CSR sampling procedure
Description: an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
Study NCT01279512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
Study NCT01279512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
Study NCT04300686 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead.
Study NCT04300686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead.
Study NCT02003573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine iv
Description: decitabine iv fixed dose
Study NCT02003573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volasertib iv infusion
Description: volasertib iv infusion (Body Surface Area (BSA) based dosing)
Study NCT02105623 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Risk factor control Diet Exercise for 24months
Study NCT02105623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Risk factor control rosuvastatin 5mg/day for 24months
Study NCT01856556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074
Description: Single IV or PO administration
Study NCT01856556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV or PO placebo administration
Study NCT00271518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone (somatropin)
Description: dosing regimen is weight based.
Study NCT01536015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks
Study NCT01536015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Frequency: One patch applied every 24 hours~Duration: 10 weeks
Study NCT00511901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00511901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alpha
Study NCT00511901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niferex
Study NCT00511901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Study NCT00832234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, Dexamethasone, Rituximab
Description: The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
Study NCT02951364 — intervention group
Intervention type: DRUG
Intervention: LDV/SOF
Description: 90/400 mg tablet administered orally once daily
Study NCT02869100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02869100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sodium fluoride Positron Emission Tomography
Study NCT02869100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study NCT02869100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiography
Study NCT03110185 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EEG
Description: Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
Study NCT03110185 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fcDOT
Description: Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
Study NCT03110185 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fcMRI
Description: Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
Study NCT01455493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral daily dose
Study NCT02675127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daktavira
Description: 1 tablet contains 60 mg Daclatasvir
Study NCT02675127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daklinza
Description: 1 tablet contains 60 mg Daclatasvir
Study NCT01723254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGE-1
Description: Intramuscular, multiple dose
Study NCT02969746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Patients will take oral activated charcoal after randomization in the intervention arm.~A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)
Study NCT02949336 — intervention group
Intervention type: RADIATION
Intervention: Observational use of fluoroscopy
Description: Minimal radiation exposure (0.17 mSv) for observational purpose
Study NCT00538902 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
Study NCT00538902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg
Description: Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
Study NCT00538902 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Description: Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
Study NCT03041519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopy ablation
Description: Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
Study NCT01723254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGE-2
Description: Intramuscular, multiple dose
Study NCT01723254 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (0.9% sodium chloride)
Study NCT02668484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repositionable valve prosthesis
Description: repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
Study NCT02668484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon-expandable valve prosthesis
Description: balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
Study NCT04309136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment
Study NCT04309136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Perform surgery if operable after neoadjuvant therapy
Study NCT04309136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core needle biopsy
Description: Perform core needle biopsy if inoperable after neoadjuvant therapy
Study NCT01545154 — intervention group
Intervention type: DEVICE
Intervention: Transperineal Ultrasound
Study NCT03451760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feru-guard 100M
Description: Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
Study NCT03451760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feru-guard 100M Placebo
Description: In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
Study NCT02422862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC-TSM
Description: Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization.
Study NCT03944473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
Study NCT03944473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
Study NCT01257425 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Description: Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85.